Table 2. Pattern of antigen expression by tumor cells from different diagnostic categories of pediatric solid tumors.
| WHO diagnosis | Immunophenotypic markers | |||||||||||||||||||
| CD45 | CD56 | CD57 | CD58 | CD90 | GD2 | CD9 | CD81 | CD99 | Myogenin | MYOD1 | CD34 | CD117 | EpCAM | CD19 | smCD3 | CD4 | CD10 | CD38 | CD271 | |
| Neuroblastoma (n = 12)* | − | +hi | +het | +het | +hi | +hi | +hi | +hi | − | − | − | − | +het | − | − | − | − | − | − | +lo |
| % of positive tumor cells | 100±0 | 93±9 | 80±30 | 95±17 | 100 | 89±20 | 100±0 | 63±26 | 44±0§ | |||||||||||
| N of positive cases | (12/12) | (8/12) | (3/12) | (11/12) | (12/12) | (12/12) | (12/12) | (8/12) | (1/12) | |||||||||||
| PNET (n = 2) | − | +het | +het | + | +hi | +lo | +hi | +hi | +hi | − | − | − | +het | − | − | − | − | − | − | +hi |
| % of positive tumor cells | 97±5 | 54±0§ | 100±0 | 100±0 | 48±0 | 100 | 100 | 100 | 58±16 | 100±0 | ||||||||||
| N of positive cases | (2/2) | (1/2) | (2/2) | (2/2) | (1/2) | (2/2) | (2/2) | (2/2) | (2/2) | (2/2) | ||||||||||
| Rhabdomyosarcoma (n = 4) | − | +lo | − | +het | +hi | +het | +het | + | +hi | +hi | − | − | − | − | − | − | − | − | − | |
| % of positive tumor cells | 69±37 | 67±0§ | 74±23 | 30±4 | 27±63 | 41±0§ | 100±0 | 100±0 | ||||||||||||
| N of positive cases | (4/4) | (1/4) | (3/4) | (2/4) | (2/4) | (1/4) | (4/4) | (4/4) | ||||||||||||
| Adrenal carcinoma (n = 1) | − | +het | − | +lo | +het | − | +het | − | − | − | − | − | − | +hi | − | − | − | − | − | − |
| % of positive tumor cells | 100 | 48 | 91 | 84 | 78 | |||||||||||||||
| Nasopharyngeal carcinoma (n = 1) | − | +hi | − | +lo | + | − | + | + | − | − | − | − | − | +hi | − | − | − | − | − | − |
| % of positive tumor cells | 100 | 61 | 96 | 100 | 100 | 82 | ||||||||||||||
| Germ cell tumor (n = 3) | − | +het | − | − | +het | − | +het | + | − | − | − | − | − | − | − | +het | − | − | ||
| % of positive tumor cells | 74±37 | 57±0§ | 67±0§ | 82±0§ | 63±0§ | |||||||||||||||
| N of positive cases | (2/3) | (1/3) | (1/3) | (1/3) | (1/3) | |||||||||||||||
| Hemangiopericytoma (n = 1) | − | − | − | − | − | − | − | − | − | − | − | +hi | − | − | − | − | − | − | − | − |
| % of positive tumor cells | 100 | |||||||||||||||||||
| Wilms Tumor (n = 2) | − | +hi | − | +lo | − | − | +het | +het | − | − | − | − | − | + | − | − | − | − | − | +het |
| % of positive tumor cells | 100±0 | 100±0 | 93±10 | 94±9 | 22±2 | 97±0§ | ||||||||||||||
| N of positive cases | (2/2) | (2/2) | (2/2) | (2/2) | (2/2) | (1/2) | ||||||||||||||
| Burkitt lymphoma (n = 3) | + | + | − | − | − | − | + | + | − | − | − | − | − | − | +hi | − | − | +hi | +hi | − |
| % of positive tumor cells | 100±0 | 100±0§ | 78±31 | 100±0§ | 100±0 | 100±0 | 100±0 | |||||||||||||
| N of positive cases | (3/3) | (1/3) | (2/3) | (1/3) | (3/3) | (3/3) | (3/3) | |||||||||||||
| B−lymphoblastic lymphoma (n = 2) | +lo | − | − | + | − | − | + | + | − | − | − | − | − | − | +hi | − | − | − | +hi | − |
| % of positive tumor cells | 100±0 | 100±0 | 100±0 | 100±0 | 100±0 | 100±0 | ||||||||||||||
| N of positive cases | (2/2) | (2/2) | (2/2) | (2/2) | (2/2) | (2/2) | ||||||||||||||
| EBV-related T-lymphoma (n = 2) | + | − | − | + | − | − | − | − | + | − | − | − | − | − | − | + | + | − | − | − |
| % of positive tumor cells | 100±0 | 100±0 | 100±0 | 91±5 | 89±5 | |||||||||||||||
| N of positive cases | (2/2) | (2/2) | (2/2) | (2/2) | (2/2) | |||||||||||||||
−: negative; +lo :low expression levels/cells; +: positive; +hi: strong expression levels/cells.
Both CD7 and CD8 were systematically negative in all tumors analyzed.
*
The only ganglioneuroblastoma tumor analyzed showed a similar profile but it contained two distinct populations which differed on CD56, CD9 and CD81 expression, in the absence of CD117.
CD271 was only partially present in one neuroblastoma tumor.
§
% of positive cells only among positive case.